Alvotech and Teva set U.S. market entry Date for Eylea® biosimilar AVT06
Alvotech (NASDAQ:ALVO) and Teva (NYSE:TEVA) have secured a U.S. market entry date for their proposed biosimilar to Eylea® (aflibercept), AVT06, under a settlement agreement with Regeneron.























